Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market By End-User (Hospitals and Clinics, Physicians Office, Outpatient Infusion Centers, Others), By Application (Emphysema, Alpha-1, Others), By Recommended Dose (60 mg/kg IV (Weekly), Others), By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The alpha1 antitrypsin deficiency (AATD) is a hereditary disorder. This disorder is characterized by a lack or deficiency of alpha1 antitrypsin in the blood, a protein that is important for the proper and healthy functioning of the lungs. The respiratory deficiency was first identified by Carl-Bertil Laurell and Sten Eriksson (Laurell and Eriksson 1963) in 1963. They discovered a link between low plasma serum AAT levels and pulmonary emphysema symptoms. As the understanding of the genetic abnormalities grew with time, AAT deficiency came to be recognized as one of the most common hereditary disorders globally. The alpha1-antitrypsin deficiency (AATD) therapy involves extracting AAT protein from a healthy donor’s blood plasma for increasing AAT levels in the respiratory tract of patients. This treatment has also been found to delay the progression of emphysema, minimize the frequency of exacerbations and improve recovery speed, a factor that has led to its increasing preference among both the patients and healthcare providers. Hence, the increasing prevalence of respiratory disorders is one of the key factors driving the growth of the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Moreover, efficient distribution of augmentation therapy drugs by leading manufacturers is also found to be propelling the market growth with a remarkable rate.
Recent advancements in diagnostic tools for genetic diseases have made revolutionary progress in the diagnosis and treatment of AATD. Patients with AATD require regular regimented care, for which augmentation therapy is specifically preferred treatment option. Hence, improved diagnostic techniques for genetic disorders, coupled with rising prevalence of AATD are significantly boosting the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Moreover, manufacturers and researchers are also currently striving to find effective ways to provide the therapy with more flexibility in their treatment regimen. Various established pharmaceutical players such as Biocerna LLC and Octapharma are engaged in conducting research on new and existing molecules for the betterment of AATD treatment scenario.
In terms of revenue, global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market was valued at US$ 1217.34 Mn in 2020 and is anticipated to reach US$ 2052.93 Mn by 2029 growing at a CAGR of 6.0% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue & Forecast, (US$ Million), 2015 – 2029
End User Outlook:
Based on end-user, the market is bifurcated into hospitals and clinics, physician’s office, outpatient infusion centers and others. Hospitals and clinics segment dominated the alpha-1 antitrypsin deficiency (AATD) augmentation therapy market, in terms of its share in 2020 due to rising patients of COPD and increased number of patients coming in through reimbursement programs such as Medicare. Also clinics segment is growing at the same market share owing to the growing number of patients opting for specialty clinics when it comes to treatment of AATD.
Application Outlook:
Based on applications, the market is segmented into emphysema, Alpha-1, and others. Emphysema accounted for the highest market share in 2020 in the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. Due to the discovery of the structure and function of the AAT protein, and its subsequent isolation and purification, allowing augmentation therapy aimed at preventing progression of the emphysema, has significantly led to the growth of this segment.
Region Outlook:
Based on the regions, North America accounted for a significant share in the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market in 2020. The dominance is attributable to the rising prevalence of the disease in the U.S and strategic presence of key companies in this region. For instance, leading AATD company, Grifols, S.A., received FDA U.S.A’s approval for A1AT genotyping test for the diagnosis of alpha-1 antitrypsin deficiency which will serve as an innovative genetic test enabling precise and early detection. These factors are driving the demand of alpha-1 antitrypsin deficiency (AATD) augmentation therapy market in the North American region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market are Abeona Therapeutics Inc., Baxter, CSL, Grifols, S.A., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, and other market participants.
Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market
By End-User
- Hospitals and Clinics
- Physicians Office
- Outpatient Infusion Centers
- Others
By Application
- Emphysema
- Alpha-1
- Others
By Recommended Dose
- 60 mg/kg IV (Weekly)
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market
6. Market Synopsis: Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market
7. Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market
7.6. Porter’s
Five Force Analysis
8.
Global Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Analysis and Forecasts, 2020 –
2028
8.1.
Overview
8.1.1.
Global Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn)
8.2.
Global Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
8.2.1.
Hospitals and Clinics
8.2.1.1.
Definition
8.2.1.2.
Market Estimation and
Penetration, 2015 – 2019
8.2.1.3.
Market Forecast, 2020 – 2028
8.2.1.4.
Compound Annual Growth Rate
(CAGR)
8.2.1.5.
Regional Bifurcation
8.2.1.5.1.
North America
8.2.1.5.1.1.
Market Estimation, 2015 – 2019
8.2.1.5.1.2.
Market Forecast, 2020 – 2028
8.2.1.5.2.
Europe
8.2.1.5.2.1.
Market Estimation, 2015 – 2019
8.2.1.5.2.2.
Market Forecast, 2020 – 2028
8.2.1.5.3.
Asia Pacific
8.2.1.5.3.1.
Market Estimation, 2015 – 2019
8.2.1.5.3.2.
Market Forecast, 2020 – 2028
8.2.1.5.4.
Middle East and Africa
8.2.1.5.4.1.
Market Estimation, 2015 – 2019
8.2.1.5.4.2.
Market Forecast, 2020 – 2028
8.2.1.5.5.
Latin America
8.2.1.5.5.1.
Market Estimation, 2015 – 2019
8.2.1.5.5.2.
Market Forecast, 2020 – 2028
8.2.2.
Physicians Office
8.2.2.1.
Definition
8.2.2.2.
Market Estimation and
Penetration, 2015 – 2019
8.2.2.3.
Market Forecast, 2020 – 2028
8.2.2.4.
Compound Annual Growth Rate
(CAGR)
8.2.2.5.
Regional Bifurcation
8.2.2.5.1.
North America
8.2.2.5.1.1.
Market Estimation, 2015 – 2019
8.2.2.5.1.2.
Market Forecast, 2020 – 2028
8.2.2.5.2.
Europe
8.2.2.5.2.1.
Market Estimation, 2015 – 2019
8.2.2.5.2.2.
Market Forecast, 2020 – 2028
8.2.2.5.3.
Asia Pacific
8.2.2.5.3.1.
Market Estimation, 2015 – 2019
8.2.2.5.3.2.
Market Forecast, 2020 – 2028
8.2.2.5.4.
Middle East and Africa
8.2.2.5.4.1.
Market Estimation, 2015 – 2019
8.2.2.5.4.2.
Market Forecast, 2020 – 2028
8.2.2.5.5.
Latin America
8.2.2.5.5.1.
Market Estimation, 2015 – 2019
8.2.2.5.5.2.
Market Forecast, 2020 – 2028
8.2.3.
Outpatient Infusion Centers
8.2.3.1.
Definition
8.2.3.2.
Market Estimation and
Penetration, 2015 – 2019
8.2.3.3.
Market Forecast, 2020 – 2028
8.2.3.4.
Compound Annual Growth Rate
(CAGR)
8.2.3.5.
Regional Bifurcation
8.2.3.5.1.
North America
8.2.3.5.1.1.
Market Estimation, 2015 – 2019
8.2.3.5.1.2.
Market Forecast, 2020 – 2028
8.2.3.5.2.
Europe
8.2.3.5.2.1.
Market Estimation, 2015 – 2019
8.2.3.5.2.2.
Market Forecast, 2020 – 2028
8.2.3.5.3.
Asia Pacific
8.2.3.5.3.1.
Market Estimation, 2015 – 2019
8.2.3.5.3.2.
Market Forecast, 2020 – 2028
8.2.3.5.4.
Middle East and Africa
8.2.3.5.4.1.
Market Estimation, 2015 – 2019
8.2.3.5.4.2.
Market Forecast, 2020 – 2028
8.2.3.5.5.
Latin America
8.2.3.5.5.1.
Market Estimation, 2015 – 2019
8.2.3.5.5.2.
Market Forecast, 2020 – 2028
8.2.4.
Others
8.2.4.1.
Definition
8.2.4.2.
Market Estimation and
Penetration, 2015 – 2019
8.2.4.3.
Market Forecast, 2020 – 2028
8.2.4.4.
Compound Annual Growth Rate
(CAGR)
8.2.4.5.
Regional Bifurcation
8.2.4.5.1.
North America
8.2.4.5.1.1.
Market Estimation, 2015 – 2019
8.2.4.5.1.2.
Market Forecast, 2020 – 2028
8.2.4.5.2.
Europe
8.2.4.5.2.1.
Market Estimation, 2015 – 2019
8.2.4.5.2.2.
Market Forecast, 2020 – 2028
8.2.4.5.3.
Asia Pacific
8.2.4.5.3.1.
Market Estimation, 2015 – 2019
8.2.4.5.3.2.
Market Forecast, 2020 – 2028
8.2.4.5.4.
Middle East and Africa
8.2.4.5.4.1.
Market Estimation, 2015 – 2019
8.2.4.5.4.2.
Market Forecast, 2020 – 2028
8.2.4.5.5.
Latin America
8.2.4.5.5.1.
Market Estimation, 2015 – 2019
8.2.4.5.5.2.
Market Forecast, 2020 – 2028
8.3.
Key Segment for Channeling
Investments
8.3.1.
By End-User
9.
Global Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Analysis and Forecasts, 2020 –
2028
9.1.
Overview
9.2.
Global Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
9.2.1.
Emphysema
9.2.1.1.
Definition
9.2.1.2.
Market Estimation and
Penetration, 2015 – 2019
9.2.1.3.
Market Forecast, 2020 – 2028
9.2.1.4.
Compound Annual Growth Rate
(CAGR)
9.2.1.5.
Regional Bifurcation
9.2.1.5.1.
North America
9.2.1.5.1.1.
Market Estimation, 2015 – 2019
9.2.1.5.1.2.
Market Forecast, 2020 – 2028
9.2.1.5.2.
Europe
9.2.1.5.2.1.
Market Estimation, 2015 – 2019
9.2.1.5.2.2.
Market Forecast, 2020 – 2028
9.2.1.5.3.
Asia Pacific
9.2.1.5.3.1.
Market Estimation, 2015 – 2019
9.2.1.5.3.2.
Market Forecast, 2020 – 2028
9.2.1.5.4.
Middle East and Africa
9.2.1.5.4.1.
Market Estimation, 2015 – 2019
9.2.1.5.4.2.
Market Forecast, 2020 – 2028
9.2.1.5.5.
Latin America
9.2.1.5.5.1.
Market Estimation, 2015 – 2019
9.2.1.5.5.2.
Market Forecast, 2020 – 2028
9.2.2.
Alpha-1
9.2.2.1.
Definition
9.2.2.2.
Market Estimation and
Penetration, 2015 – 2019
9.2.2.3.
Market Forecast, 2020 – 2028
9.2.2.4.
Compound Annual Growth Rate
(CAGR)
9.2.2.5.
Regional Bifurcation
9.2.2.5.1.
North America
9.2.2.5.1.1.
Market Estimation, 2015 – 2019
9.2.2.5.1.2.
Market Forecast, 2020 – 2028
9.2.2.5.2.
Europe
9.2.2.5.2.1.
Market Estimation, 2015 – 2019
9.2.2.5.2.2.
Market Forecast, 2020 – 2028
9.2.2.5.3.
Asia Pacific
9.2.2.5.3.1.
Market Estimation, 2015 – 2019
9.2.2.5.3.2.
Market Forecast, 2020 – 2028
9.2.2.5.4.
Middle East and Africa
9.2.2.5.4.1.
Market Estimation, 2015 – 2019
9.2.2.5.4.2.
Market Forecast, 2020 – 2028
9.2.2.5.5.
Latin America
9.2.2.5.5.1.
Market Estimation, 2015 – 2019
9.2.2.5.5.2.
Market Forecast, 2020 – 2028
9.2.3.
Others
9.2.3.1.
Definition
9.2.3.2.
Market Estimation and
Penetration, 2015 – 2019
9.2.3.3.
Market Forecast, 2020 – 2028
9.2.3.4.
Compound Annual Growth Rate
(CAGR)
9.2.3.5.
Regional Bifurcation
9.2.3.5.1.
North America
9.2.3.5.1.1.
Market Estimation, 2015 – 2019
9.2.3.5.1.2.
Market Forecast, 2020 – 2028
9.2.3.5.2.
Europe
9.2.3.5.2.1.
Market Estimation, 2015 – 2019
9.2.3.5.2.2.
Market Forecast, 2020 – 2028
9.2.3.5.3.
Asia Pacific
9.2.3.5.3.1.
Market Estimation, 2015 – 2019
9.2.3.5.3.2.
Market Forecast, 2020 – 2028
9.2.3.5.4.
Middle East and Africa
9.2.3.5.4.1.
Market Estimation, 2015 – 2019
9.2.3.5.4.2.
Market Forecast, 2020 – 2028
9.2.3.5.5.
Latin America
9.2.3.5.5.1.
Market Estimation, 2015 – 2019
9.2.3.5.5.2.
Market Forecast, 2020 – 2028
9.3.
Key Segment for Channeling
Investments
9.3.1.
By Application
10. Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Revenue (US$ Mn) and Forecasts, By Recommended Dose
10.2.1. 60 mg/kg IV (Weekly)
10.2.1.1.
Definition
10.2.1.2.
Market Estimation and
Penetration, 2015 – 2019
10.2.1.3.
Market Forecast, 2020 – 2028
10.2.1.4.
Compound Annual Growth Rate
(CAGR)
10.2.1.5.
Regional Bifurcation
10.2.1.5.1.
North America
10.2.1.5.1.1.
Market Estimation, 2015 – 2019
10.2.1.5.1.2.
Market Forecast, 2020 – 2028
10.2.1.5.2.
Europe
10.2.1.5.2.1.
Market Estimation, 2015 – 2019
10.2.1.5.2.2.
Market Forecast, 2020 – 2028
10.2.1.5.3.
Asia Pacific
10.2.1.5.3.1.
Market Estimation, 2015 – 2019
10.2.1.5.3.2.
Market Forecast, 2020 – 2028
10.2.1.5.4.
Middle East and Africa
10.2.1.5.4.1.
Market Estimation, 2015 – 2019
10.2.1.5.4.2.
Market Forecast, 2020 – 2028
10.2.1.5.5.
Latin America
10.2.1.5.5.1.
Market Estimation, 2015 – 2019
10.2.1.5.5.2.
Market Forecast, 2020 – 2028
10.2.2. Others
10.2.2.1.
Definition
10.2.2.2.
Market Estimation and
Penetration, 2015 – 2019
10.2.2.3.
Market Forecast, 2020 – 2028
10.2.2.4.
Compound Annual Growth Rate
(CAGR)
10.2.2.5.
Regional Bifurcation
10.2.2.5.1.
North America
10.2.2.5.1.1.
Market Estimation, 2015 – 2019
10.2.2.5.1.2.
Market Forecast, 2020 – 2028
10.2.2.5.2.
Europe
10.2.2.5.2.1.
Market Estimation, 2015 – 2019
10.2.2.5.2.2.
Market Forecast, 2020 – 2028
10.2.2.5.3.
Asia Pacific
10.2.2.5.3.1.
Market Estimation, 2015 – 2019
10.2.2.5.3.2.
Market Forecast, 2020 – 2028
10.2.2.5.4.
Middle East and Africa
10.2.2.5.4.1.
Market Estimation, 2015 – 2019
10.2.2.5.4.2.
Market Forecast, 2020 – 2028
10.2.2.5.5.
Latin America
10.2.2.5.5.1.
Market Estimation, 2015 – 2019
10.2.2.5.5.2.
Market Forecast, 2020 – 2028
10.3. Key Segment for Channeling Investments
10.3.1. By Recommended Dose
11. North America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Analysis and Forecasts, 2020 - 2028
11.1. Overview
11.1.1. North America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn)
11.2. North America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
11.2.1. Hospitals and Clinics
11.2.2. Physicians Office
11.2.3. Outpatient Infusion Centers
11.2.4. Others
11.3. North America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1. Emphysema
11.3.2. Alpha-1
11.3.3. Others
11.4. North America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Recommended Dose
11.4.1. 60 mg/kg IV (Weekly)
11.4.2. Others
11.5. North America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1.
U.S Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
11.5.1.1.1.
Hospitals and Clinics
11.5.1.1.2.
Physicians Office
11.5.1.1.3.
Outpatient Infusion Centers
11.5.1.1.4.
Others
11.5.1.2.
U.S Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.1.2.1.
Emphysema
11.5.1.2.2.
Alpha-1
11.5.1.2.3.
Others
11.5.1.3.
U.S Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
11.5.1.3.1.
60 mg/kg IV (Weekly)
11.5.1.3.2.
Others
11.5.2. Canada
11.5.2.1.
Canada Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
11.5.2.1.1.
Hospitals and Clinics
11.5.2.1.2.
Physicians Office
11.5.2.1.3.
Outpatient Infusion Centers
11.5.2.1.4.
Others
11.5.2.2.
Canada Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.2.2.1.
Emphysema
11.5.2.2.2.
Alpha-1
11.5.2.2.3.
Others
11.5.2.3.
Canada Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
11.5.2.3.1.
60 mg/kg IV (Weekly)
11.5.2.3.2.
Others
11.5.3. Mexico
11.5.3.1.
Mexico Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
11.5.3.1.1.
Hospitals and Clinics
11.5.3.1.2.
Physicians Office
11.5.3.1.3.
Outpatient Infusion Centers
11.5.3.1.4.
Others
11.5.3.2.
Mexico Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
11.5.3.2.1.
Emphysema
11.5.3.2.2.
Alpha-1
11.5.3.2.3.
Others
11.5.3.3.
Mexico Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
11.5.3.3.1.
60 mg/kg IV (Weekly)
11.5.3.3.2.
Others
11.5.4. Rest of North America
11.5.4.1.
Rest of North America Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
11.5.4.1.1.
Hospitals and Clinics
11.5.4.1.2.
Physicians Office
11.5.4.1.3.
Outpatient Infusion Centers
11.5.4.1.4.
Others
11.5.4.2.
Rest of North America Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.4.2.1.
Emphysema
11.5.4.2.2.
Alpha-1
11.5.4.2.3.
Others
11.5.4.3.
Rest of North America Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
11.5.4.3.1.
60 mg/kg IV (Weekly)
11.5.4.3.2.
Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By End-User
11.6.3. By Application
11.6.4. By Recommended Dose
12. Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Revenue (US$ Mn)
12.2. Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
12.2.1. Hospitals and Clinics
12.2.2. Physicians Office
12.2.3. Outpatient Infusion Centers
12.2.4. Others
12.3. Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Emphysema
12.3.2. Alpha-1
12.3.3. Others
12.4. Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Revenue (US$ Mn) and Forecasts, By Recommended Dose
12.4.1. 60 mg/kg IV (Weekly)
12.4.2. Others
12.5. Europe Alpha-1 Antitrypsin Deficiency (AATD) Augmentation
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1.
France Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
12.5.1.1.1.
Hospitals and Clinics
12.5.1.1.2.
Physicians Office
12.5.1.1.3.
Outpatient Infusion Centers
12.5.1.1.4.
Others
12.5.1.2.
France Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.1.2.1.
Emphysema
12.5.1.2.2.
Alpha-1
12.5.1.2.3.
Others
12.5.1.3.
France Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
12.5.1.3.1.
60 mg/kg IV (Weekly)
12.5.1.3.2.
Others
12.5.2. The UK
12.5.2.1.
The UK Alpha-1 Antitrypsin Deficiency
(AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.2.1.1.
Hospitals and Clinics
12.5.2.1.2.
Physicians Office
12.5.2.1.3.
Outpatient Infusion Centers
12.5.2.1.4.
Others
12.5.2.2.
The UK Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.2.2.1.
Emphysema
12.5.2.2.2.
Alpha-1
12.5.2.2.3.
Others
12.5.2.3.
The UK Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
12.5.2.3.1.
60 mg/kg IV (Weekly)
12.5.2.3.2.
Others
12.5.3. Spain
12.5.3.1.
Spain Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
12.5.3.1.1.
Hospitals and Clinics
12.5.3.1.2.
Physicians Office
12.5.3.1.3.
Outpatient Infusion Centers
12.5.3.1.4.
Others
12.5.3.2.
Spain Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.3.2.1.
Emphysema
12.5.3.2.2.
Alpha-1
12.5.3.2.3.
Others
12.5.3.3.
Spain Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
12.5.3.3.1.
60 mg/kg IV (Weekly)
12.5.3.3.2.
Others
12.5.4. Germany
12.5.4.1.
Germany Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
12.5.4.1.1.
Hospitals and Clinics
12.5.4.1.2.
Physicians Office
12.5.4.1.3.
Outpatient Infusion Centers
12.5.4.1.4.
Others
12.5.4.2.
Germany Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.4.2.1.
Emphysema
12.5.4.2.2.
Alpha-1
12.5.4.2.3.
Others
12.5.4.3.
Germany Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
12.5.4.3.1.
60 mg/kg IV (Weekly)
12.5.4.3.2.
Others
12.5.5. Italy
12.5.5.1.
Italy Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
12.5.5.1.1.
Hospitals and Clinics
12.5.5.1.2.
Physicians Office
12.5.5.1.3.
Outpatient Infusion Centers
12.5.5.1.4.
Others
12.5.5.2.
Italy Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.5.2.1.
Emphysema
12.5.5.2.2.
Alpha-1
12.5.5.2.3.
Others
12.5.5.3.
Italy Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
12.5.5.3.1.
60 mg/kg IV (Weekly)
12.5.5.3.2.
Others
12.5.6. Nordic Countries
12.5.6.1.
Nordic Countries Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
12.5.6.1.1.
Hospitals and Clinics
12.5.6.1.2.
Physicians Office
12.5.6.1.3.
Outpatient Infusion Centers
12.5.6.1.4.
Others
12.5.6.2.
Nordic Countries Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
12.5.6.2.1.
Emphysema
12.5.6.2.2.
Alpha-1
12.5.6.2.3.
Others
12.5.6.3.
Nordic Countries Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
12.5.6.3.1.
60 mg/kg IV (Weekly)
12.5.6.3.2.
Others
12.5.6.4.
Nordic Countries Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.6.4.1.
Denmark
12.5.6.4.2.
Finland
12.5.6.4.3.
Iceland
12.5.6.4.4.
Sweden
12.5.6.4.5.
Norway
12.5.7. Benelux Union
12.5.7.1.
Benelux Union Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
12.5.7.1.1.
Hospitals and Clinics
12.5.7.1.2.
Physicians Office
12.5.7.1.3.
Outpatient Infusion Centers
12.5.7.1.4.
Others
12.5.7.2.
Benelux Union Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.7.2.1.
Emphysema
12.5.7.2.2.
Alpha-1
12.5.7.2.3.
Others
12.5.7.3.
Benelux Union Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
12.5.7.3.1.
60 mg/kg IV (Weekly)
12.5.7.3.2.
Others
12.5.7.4.
Benelux Union Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Country
12.5.7.4.1.
Belgium
12.5.7.4.2.
The Netherlands
12.5.7.4.3.
Luxembourg
12.5.8. Rest of Europe
12.5.8.1.
Rest of Europe Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
12.5.8.1.1.
Hospitals and Clinics
12.5.8.1.2.
Physicians Office
12.5.8.1.3.
Outpatient Infusion Centers
12.5.8.1.4.
Others
12.5.8.2.
Rest of Europe Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.8.2.1.
Emphysema
12.5.8.2.2.
Alpha-1
12.5.8.2.3.
Others
12.5.8.3.
Rest of Europe Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
12.5.8.3.1.
60 mg/kg IV (Weekly)
12.5.8.3.2.
Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By End-User
12.6.3. By Application
12.6.4. By Recommended Dose
13. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn)
13.2. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
13.2.1. Hospitals and Clinics
13.2.2. Physicians Office
13.2.3. Outpatient Infusion Centers
13.2.4. Others
13.3. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Emphysema
13.3.2. Alpha-1
13.3.3. Others
13.4. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Recommended Dose
13.4.1. 60 mg/kg IV (Weekly)
13.4.2. Others
13.5. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1.
China Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.1.1.1.
Hospitals and Clinics
13.5.1.1.2.
Physicians Office
13.5.1.1.3.
Outpatient Infusion Centers
13.5.1.1.4.
Others
13.5.1.2.
China Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.1.2.1.
Emphysema
13.5.1.2.2.
Alpha-1
13.5.1.2.3.
Others
13.5.1.3.
China Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
13.5.1.3.1.
60 mg/kg IV (Weekly)
13.5.1.3.2.
Others
13.5.2. Japan
13.5.2.1.
Japan Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.2.1.1.
Hospitals and Clinics
13.5.2.1.2.
Physicians Office
13.5.2.1.3.
Outpatient Infusion Centers
13.5.2.1.4.
Others
13.5.2.2.
Japan Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.2.2.1.
Emphysema
13.5.2.2.2.
Alpha-1
13.5.2.2.3.
Others
13.5.2.3.
Japan Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
13.5.2.3.1.
60 mg/kg IV (Weekly)
13.5.2.3.2.
Others
13.5.3. India
13.5.3.1.
India Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.3.1.1.
Hospitals and Clinics
13.5.3.1.2.
Physicians Office
13.5.3.1.3.
Outpatient Infusion Centers
13.5.3.1.4.
Others
13.5.3.2.
India Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.3.2.1.
Emphysema
13.5.3.2.2.
Alpha-1
13.5.3.2.3.
Others
13.5.3.3.
India Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
13.5.3.3.1.
60 mg/kg IV (Weekly)
13.5.3.3.2.
Others
13.5.4. New Zealand
13.5.4.1.
New Zealand Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.4.1.1.
Hospitals and Clinics
13.5.4.1.2.
Physicians Office
13.5.4.1.3.
Outpatient Infusion Centers
13.5.4.1.4.
Others
13.5.4.2.
New Zealand Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.4.2.1.
Emphysema
13.5.4.2.2.
Alpha-1
13.5.4.2.3.
Others
13.5.4.3.
New Zealand Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
13.5.4.3.1.
60 mg/kg IV (Weekly)
13.5.4.3.2.
Others
13.5.5. Australia
13.5.5.1.
Australia Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.5.1.1.
Hospitals and Clinics
13.5.5.1.2.
Physicians Office
13.5.5.1.3.
Outpatient Infusion Centers
13.5.5.1.4.
Others
13.5.5.2.
Australia Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.5.2.1.
Emphysema
13.5.5.2.2.
Alpha-1
13.5.5.2.3.
Others
13.5.5.3.
Australia Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
13.5.5.3.1.
60 mg/kg IV (Weekly)
13.5.5.3.2.
Others
13.5.6. South Korea
13.5.6.1.
South Korea Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.6.1.1.
Hospitals and Clinics
13.5.6.1.2.
Physicians Office
13.5.6.1.3.
Outpatient Infusion Centers
13.5.6.1.4.
Others
13.5.6.2.
South Korea Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.6.2.1.
Emphysema
13.5.6.2.2.
Alpha-1
13.5.6.2.3.
Others
13.5.6.3.
South Korea Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
13.5.6.3.1.
60 mg/kg IV (Weekly)
13.5.6.3.2.
Others
13.5.7. Southeast Asia
13.5.7.1.
Southeast Asia Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
13.5.7.1.1.
Hospitals and Clinics
13.5.7.1.2.
Physicians Office
13.5.7.1.3.
Outpatient Infusion Centers
13.5.7.1.4.
Others
13.5.7.2.
Southeast Asia Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.7.2.1.
Emphysema
13.5.7.2.2.
Alpha-1
13.5.7.2.3.
Others
13.5.7.3.
Southeast Asia Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
13.5.7.3.1.
60 mg/kg IV (Weekly)
13.5.7.3.2.
Others
13.5.7.4.
Southeast Asia Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.7.4.1.
Indonesia
13.5.7.4.2.
Thailand
13.5.7.4.3.
Malaysia
13.5.7.4.4.
Singapore
13.5.7.4.5.
Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1.
Rest of Asia Pacific Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
13.5.8.1.1.
Hospitals and Clinics
13.5.8.1.2.
Physicians Office
13.5.8.1.3.
Outpatient Infusion Centers
13.5.8.1.4.
Others
13.5.8.2.
Rest of Asia Pacific Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.8.2.1.
Emphysema
13.5.8.2.2.
Alpha-1
13.5.8.2.3.
Others
13.5.8.3.
Rest of Asia Pacific Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
13.5.8.3.1.
60 mg/kg IV (Weekly)
13.5.8.3.2.
Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By End-User
13.6.3. By Application
13.6.4. By Recommended Dose
14. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn)
14.2. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
14.2.1. Hospitals and Clinics
14.2.2. Physicians Office
14.2.3. Outpatient Infusion Centers
14.2.4. Others
14.3. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1. Emphysema
14.3.2. Alpha-1
14.3.3. Others
14.4. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Recommended Dose
14.4.1. 60 mg/kg IV (Weekly)
14.4.2. Others
14.5. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1.
Saudi Arabia Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
14.5.1.1.1.
Hospitals and Clinics
14.5.1.1.2.
Physicians Office
14.5.1.1.3.
Outpatient Infusion Centers
14.5.1.1.4.
Others
14.5.1.2.
Saudi Arabia Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.1.2.1.
Emphysema
14.5.1.2.2.
Alpha-1
14.5.1.2.3.
Others
14.5.1.3.
Saudi Arabia Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
14.5.1.3.1.
60 mg/kg IV (Weekly)
14.5.1.3.2.
Others
14.5.2. UAE
14.5.2.1.
UAE Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
14.5.2.1.1.
Hospitals and Clinics
14.5.2.1.2.
Physicians Office
14.5.2.1.3.
Outpatient Infusion Centers
14.5.2.1.4.
Others
14.5.2.2.
UAE Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.2.2.1.
Emphysema
14.5.2.2.2.
Alpha-1
14.5.2.2.3.
Others
14.5.2.3.
UAE Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
14.5.2.3.1.
60 mg/kg IV (Weekly)
14.5.2.3.2.
Others
14.5.3. Egypt
14.5.3.1.
Egypt Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
14.5.3.1.1.
Hospitals and Clinics
14.5.3.1.2.
Physicians Office
14.5.3.1.3.
Outpatient Infusion Centers
14.5.3.1.4.
Others
14.5.3.2.
Egypt Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.3.2.1.
Emphysema
14.5.3.2.2.
Alpha-1
14.5.3.2.3.
Others
14.5.3.3.
Egypt Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
14.5.3.3.1.
60 mg/kg IV (Weekly)
14.5.3.3.2.
Others
14.5.4. Kuwait
14.5.4.1.
Kuwait Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
14.5.4.1.1.
Hospitals and Clinics
14.5.4.1.2.
Physicians Office
14.5.4.1.3.
Outpatient Infusion Centers
14.5.4.1.4.
Others
14.5.4.2.
Kuwait Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.4.2.1.
Emphysema
14.5.4.2.2.
Alpha-1
14.5.4.2.3.
Others
14.5.4.3.
Kuwait Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
14.5.4.3.1.
60 mg/kg IV (Weekly)
14.5.4.3.2.
Others
14.5.5. South Africa
14.5.5.1.
South Africa Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
14.5.5.1.1.
Hospitals and Clinics
14.5.5.1.2.
Physicians Office
14.5.5.1.3.
Outpatient Infusion Centers
14.5.5.1.4.
Others
14.5.5.2.
South Africa Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
14.5.5.2.1.
Emphysema
14.5.5.2.2.
Alpha-1
14.5.5.2.3.
Others
14.5.5.3.
South Africa Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
14.5.5.3.1.
60 mg/kg IV (Weekly)
14.5.5.3.2.
Others
14.5.6. Rest of Middle East & Africa
14.5.6.1.
Rest of Middle East & Africa
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$
Mn) and Forecasts, By End-User
14.5.6.1.1.
Hospitals and Clinics
14.5.6.1.2.
Physicians Office
14.5.6.1.3.
Outpatient Infusion Centers
14.5.6.1.4.
Others
14.5.6.2.
Rest of Middle East & Africa
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$
Mn) and Forecasts, By Application
14.5.6.2.1.
Emphysema
14.5.6.2.2.
Alpha-1
14.5.6.2.3.
Others
14.5.6.3.
Rest of Middle East & Africa
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn)
and Forecasts, By Recommended Dose
14.5.6.3.1.
60 mg/kg IV (Weekly)
14.5.6.3.2.
Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By End-User
14.6.3. By Application
14.6.4. By Recommended Dose
15. Latin America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Latin America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn)
15.2. Latin America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By End-User
15.2.1. Hospitals and Clinics
15.2.2. Physicians Office
15.2.3. Outpatient Infusion Centers
15.2.4. Others
15.3. Latin America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Emphysema
15.3.2. Alpha-1
15.3.3. Others
15.4. Latin America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Recommended Dose
15.4.1. 60 mg/kg IV (Weekly)
15.4.2. Others
15.5. Latin America Alpha-1 Antitrypsin Deficiency (AATD)
Augmentation Therapy Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1.
Brazil Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
15.5.1.1.1.
Hospitals and Clinics
15.5.1.1.2.
Physicians Office
15.5.1.1.3.
Outpatient Infusion Centers
15.5.1.1.4.
Others
15.5.1.2.
Brazil Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
15.5.1.2.1.
Emphysema
15.5.1.2.2.
Alpha-1
15.5.1.2.3.
Others
15.5.1.3.
Brazil Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
15.5.1.3.1.
60 mg/kg IV (Weekly)
15.5.1.3.2.
Others
15.5.2. Argentina
15.5.2.1.
Argentina Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By End-User
15.5.2.1.1.
Hospitals and Clinics
15.5.2.1.2.
Physicians Office
15.5.2.1.3.
Outpatient Infusion Centers
15.5.2.1.4.
Others
15.5.2.2.
Argentina Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Application
15.5.2.2.1.
Emphysema
15.5.2.2.2.
Alpha-1
15.5.2.2.3.
Others
15.5.2.3.
Argentina Alpha-1 Antitrypsin
Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and Forecasts,
By Recommended Dose
15.5.2.3.1.
60 mg/kg IV (Weekly)
15.5.2.3.2.
Others
15.5.3. Rest of Latin America
15.5.3.1.
Rest of Latin America Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By End-User
15.5.3.1.1.
Hospitals and Clinics
15.5.3.1.2.
Physicians Office
15.5.3.1.3.
Outpatient Infusion Centers
15.5.3.1.4.
Others
15.5.3.2.
Rest of Latin America Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.3.2.1.
Emphysema
15.5.3.2.2.
Alpha-1
15.5.3.2.3.
Others
15.5.3.3.
Rest of Latin America Alpha-1
Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue (US$ Mn) and
Forecasts, By Recommended Dose
15.5.3.3.1.
60 mg/kg IV (Weekly)
15.5.3.3.2.
Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By End-User
15.6.3. By Application
15.6.4. By Recommended Dose
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2019
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Abeona Therapeutics Inc.
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Baxter
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. CSL
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Grifols, S.A.
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Kamada Pharmaceuticals
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Takeda Pharmaceutical Company Limited
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.